☰

Suzan M. Hammond, Ph.D. - Publications

Affiliations: 
2010 Integrated Graduate Program in the Life Sciences Northwestern University, Evanston, IL 
Area:
Molecular Neuroscience, Motor Control, Neurobiology of Disease
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Hammond SM, Abendroth F, Goli L, Stoodley J, Burrell M, Thom G, Gurrell I, Ahlskog N, Gait MJ, Wood MJ, Webster CI. Antibody-oligonucleotide conjugate achieves central nervous system delivery in animal models for spinal muscular atrophy. Jci Insight. PMID 36346674 DOI: 10.1172/jci.insight.154142  0.347
2021 Winkelsas AM, Grunseich C, Harmison GG, Chwalenia K, Rinaldi C, Hammond SM, Johnson K, Bowerman M, Arya S, Talbot K, Wood MJ, Fischbeck KH. Targeting the 5' untranslated region of as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy. Nucleic Acids. 23: 731-742. PMID 33575118 DOI: 10.1016/j.omtn.2020.12.027  0.31
2020 Ahlskog N, Hayler D, Krueger A, Kubinski S, Claus P, Hammond SM, Wood MJA, Yáñez-Muñoz RJ, Bowerman M. Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. Gene Therapy. PMID 32313099 DOI: 10.1038/S41434-020-0146-8  0.456
2019 Hammond SM, Abendroth F, Gait MJ, Wood MJA. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy. Methods in Molecular Biology (Clifton, N.J.). 2036: 221-236. PMID 31410800 DOI: 10.1007/978-1-4939-9670-4_13  0.436
2018 Gait MJ, Arzumanov AA, McClorey G, Godfrey C, Betts C, Hammond S, Wood MJA. Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. Nucleic Acid Therapeutics. PMID 30307373 DOI: 10.1089/Nat.2018.0747  0.327
2018 Betts CA, McClorey G, Healicon R, Hammond SM, Manzano R, Muses S, Ball V, Godfrey C, Merritt TM, Westering T, O'Donovan L, Wells KE, Gait MJ, Wells DJ, Tyler D, et al. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Human Molecular Genetics. PMID 30281092 DOI: 10.1093/Hmg/Ddy346  0.379
2018 Walter LM, Deguise MO, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, Hazell G, McFall E, Kordala A, Hammond SM, Abendroth F, Murray LM, Shorrock HK, Prosdocimo DA, Haldar SM, et al. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. Ebiomedicine. PMID 29735415 DOI: 10.1016/J.Ebiom.2018.04.024  0.361
2017 Shabanpoor F, Hammond SM, Abendroth F, Hazell G, Wood MJ, Gait MJ. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. Nucleic Acid Therapeutics. PMID 28118087 DOI: 10.1089/Nat.2016.0652  0.44
2016 Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, Meijboom KE, Zhou H, Muntoni F, Talbot K, Gait MJ, Wood MJ. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America. PMID 27621445 DOI: 10.1073/Pnas.1605731113  0.475
2015 Betts CA, Saleh AF, Carr CA, Muses S, Wells KE, Hammond SM, Godfrey C, McClorey G, Woffindale C, Clarke K, Wells DJ, Gait MJ, Wood MJ. Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. Scientific Reports. 5: 11632. PMID 26113184 DOI: 10.1038/Srep11632  0.327
2015 Varela MA, Curtis HJ, Douglas AG, Hammond SM, O'Loughlin AJ, Sobrido MJ, Scholefield J, Wood MJ. Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases. European Journal of Human Genetics : Ejhg. PMID 25990798 DOI: 10.1038/Ejhg.2015.94  0.362
2015 Godfrey C, Muses S, McClorey G, Wells KE, Coursindel T, Terry RL, Betts C, Hammond S, O'Donovan L, Hildyard J, El Andaloussi S, Gait MJ, Wood MJ, Wells DJ. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Human Molecular Genetics. PMID 25935000 DOI: 10.1093/Hmg/Ddv155  0.347
2015 Betts CA, Saleh AF, Carr CA, Hammond SM, Coenen-Stass AM, Godfrey C, McClorey G, Varela MA, Roberts TC, Clarke K, Gait MJ, Wood MJ. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Scientific Reports. 5: 8986. PMID 25758104 DOI: 10.1038/Srep08986  0.383
2015 Järver P, Zaghloul EM, Arzumanov AA, Saleh AF, McClorey G, Hammond SM, Hällbrink M, Langel Ü, Smith CI, Wood MJ, Gait MJ, El Andaloussi S. Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Therapeutics. 25: 65-77. PMID 25594433 DOI: 10.1089/Nat.2014.0511  0.301
2015 Muses S, Godfrey C, McClorey G, Wells KE, Coursindel T, Terry RL, Betts C, Cappellari O, Hammond S, O'Donovan E, Hildyard JCW, Andaloussi SE, Gait M, Wood M, Wells DJ. The Physiological Consequences Of Different Levels Of Dystrophin Following Antisense Based Exon-Skipping In The Mdx Mouse Neuromuscular Disorders. 25. DOI: 10.1016/J.Nmd.2015.06.450  0.341
2014 Hammond SM, McClorey G, Nordin JZ, Godfrey C, Stenler S, Lennox KA, Smith CI, Jacobi AM, Varela MA, Lee Y, Behlke MA, Wood MJ, Andaloussi SE. Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. Molecular Therapy. Nucleic Acids. 3: e212. PMID 25423116 DOI: 10.1038/Mtna.2014.63  0.388
2012 Betts C, Saleh AF, Arzumanov AA, Hammond SM, Godfrey C, Coursindel T, Gait MJ, Wood MJ. Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Molecular Therapy. Nucleic Acids. 1: e38. PMID 23344180 DOI: 10.1038/Mtna.2012.30  0.359
2012 El Andaloussi SA, Hammond SM, Mäger I, Wood MJ. Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. Current Gene Therapy. 12: 161-78. PMID 22533378 DOI: 10.2174/156652312800840612  0.366
2012 Betts CA, Hammond SM, Yin HF, Wood MJ. Optimizing tissue-specific antisense oligonucleotide-peptide conjugates. Methods in Molecular Biology (Clifton, N.J.). 867: 415-35. PMID 22454077 DOI: 10.1007/978-1-61779-767-5_27  0.338
2011 Yin H, Saleh AF, Betts C, Camelliti P, Seow Y, Ashraf S, Arzumanov A, Hammond S, Merritt T, Gait MJ, Wood MJ. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1295-303. PMID 21505427 DOI: 10.1038/Mt.2011.79  0.445
2011 Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends in Genetics : Tig. 27: 196-205. PMID 21497936 DOI: 10.1016/J.Tig.2011.02.004  0.335
2011 Ezzat K, Andaloussi SE, Zaghloul EM, Lehto T, Lindberg S, Moreno PM, Viola JR, Magdy T, Abdo R, Guterstam P, Sillard R, Hammond SM, Wood MJ, Arzumanov AA, Gait MJ, et al. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research. 39: 5284-98. PMID 21345932 DOI: 10.1093/Nar/Gkr072  0.378
2011 Saleh AF, Arzumanov AA, Yin H, Betts C, Hammond S, Wood MJA, Gait MJ. Enhancement of exon skipping and dystrophin production by 3'-peptide conjugates of morpholino (PMO) oligonucleotides in a mdx mouse model of Duchenne muscular dystrophy Collection of Czechoslovak Chemical Communications. 12: 292-296. DOI: 10.1135/Css201112292  0.352
2010 Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. Plos One. 5: e15887. PMID 21249120 DOI: 10.1371/Journal.Pone.0015887  0.65
2010 Gogliotti RG, Hammond SM, Lutz C, Didonato CJ. Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochemical and Biophysical Research Communications. 391: 517-22. PMID 19961830 DOI: 10.1016/J.Bbrc.2009.11.090  0.644
2008 Heier C, Hammond S, Gogliotti R, DiDonato C. G.P.4.12 Translational readthrough modulates SMN stability: Potential for aminoglycosides as an SMA therapy Neuromuscular Disorders. 18: 763-764. DOI: 10.1016/J.Nmd.2008.06.139  0.603
2005 Hammond SM, Crable SC, Anderson KP. Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leukemia Research. 29: 89-97. PMID 15541480 DOI: 10.1016/J.Leukres.2004.05.013  0.303
2004 Anderson K, Crable SC, Hammond SM, Joiner CH, Gallagher PG. A Second Promoter for the Human KCl Cotransporter 1 (KCC1) Gene Drives Differential Expression of a Variant Isoform in Sickle Versus Normal Reticulocytes. Blood. 104: 3592-3592. DOI: 10.1182/Blood.V104.11.3592.3592  0.337
Show low-probability matches.